The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 19, 2018.
Transcript:
Hi, I’m Samantha DiGrande for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 19.
Number 5: In the latest episode of our podcast, “Not So Different,” Christine Simmon of the Biosimilars Council explains why her organization supports the CREATES Act.
Number 4: Celltrion has granted marketing rights for its trastuzumab in 7 European nations to Mundipharma.
Number 3: A recent study showed that patients with rheumatoid arthritis who use infliximab have a higher discontinuation rate due to disease remission than those patients who use other biologics.
Number 2: The FDA’s Center for Drug Evaluation and Research has launched its pilot effort to publicly release clinical study report data from pivotal clinical trials.
Number 1: An insurer is backing away from a plan to institute a nonmedical switch from brand-name Remicade to biosimilar Inflectra.
Finally, last week, our e-newsletter asked for your thoughts on which stakeholder group has the most influence on biosimilar acceptance.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.